Imagine a virus that acts like a hidden trigger, waking up the immune system to attack the brain's wiring. This project is mapping exactly how that trigger works in people with Multiple Sclerosis. By creating a 'lab-grown' version of the disease and using animal models, they are finding the exact switches to flip to stop the damage.
Current MS treatments only slow progression but cannot stop it. There is a critical lack of precise biomarkers and predictive models to identify how the Epstein-Barr virus triggers the disease in individual patients.
The project is building a comprehensive map of virus-immune interactions, an in vitro model using reprogrammed patient cells, an animal model of prodromal MS, and specific biomarkers for EBV monitoring.
If you are a drug discovery firm dealing with the lack of disease-stopping MS treatments — this project developed an animal model of prodromal MS that allows for testing of promising new treatments. This reduces the risk of clinical failure by identifying pathogenic mechanisms early.
If you are a test manufacturer dealing with imprecise MS patient stratification — this project developed biomarkers to monitor EBV infection in patients. This allows for the creation of new diagnostic tools to better manage patient risk.
If you are a biotech company dealing with the difficulty of simulating human brain disease in vitro — this project developed an in vitro model integrating virus, immune system, and reprogrammed brain cells. This provides a high-fidelity platform for testing molecular mechanisms.
Based on available project data, no pricing or cost information for the models or biomarkers has been disclosed.
The project focuses on creating research models (in vitro and animal) and biomarkers; based on available project data, industrial scaling plans are not yet specified.
Based on available project data, specific IP or licensing terms are not mentioned, though the project aims to open doors for industry to capitalize on the mechanisms.
The project runs from 2023-12-01 to 2028-11-30, suggesting that validated biomarkers and models will be available toward the end of this period.
The results are intended to empower the healthcare value chain through improved risk analysis, stratification, and new clinical guidelines.
The consortium is heavily weighted toward research and academia, consisting of 6 universities and 6 research organizations across 7 countries. With 0% industry participation and 0 SMEs, the project is currently driven by scientific discovery rather than commercial deployment, though it explicitly aims to provide tools for future industry capitalization.
Contact the Deutsches Krebsforschungszentrum Heidelberg for technical inquiries regarding EBV-MS models.
Contact us to bridge the gap between these academic models and your pharmaceutical pipeline.
